Source link : https://www.newshealth.biz/health-news/t-dxd-moves-toward-the-front-line-for-her2-low-metastatic-bc/
The antibody-drug conjugate trastuzumab deruxtecan, or T-DXd, is an effective first-line treatment in patients with HER2-low metastatic breast cancer, conferring an additional 5 months’ progression-free survival over chemotherapy. HER2-low cancers express levels of human epidermal growth factor receptor 2 that are below standard thresholds for HER2-positive immunohistochemistry. In 2022, results from the DESTINY-Breast04 trial showed […]
Author : News Health
Publish date : 2024-06-11 10:17:41
Copyright for syndicated content belongs to the linked Source.